Articles related to DEPRESSION

The idea that depression is brought on by decreased serotonin activity or concentrations is unsupported, according to the authors of a systematic umbrella review, who also challenge the rationale behind the high rates of antidepressant prescription. They claim that certain medical professionals continue to promote the incorrect chemical imbalance explanation of depression, and the public as a whole still accepts it. However, other medical professionals argue that antidepressants continue to be a helpful treatment option for patients in addition to other methods like talking therapy and that the idea that depression is caused by a straightforward chemical imbalance is outdated in any case.

Using covariate analysis of records from more than 1.2 million children over 17 years, these researchers conclude that the elevated risk for neonatal seizures and childhood epilepsy in children who were exposed to SSRIs or SNRIs during pregnancy can be attributed to the indicated SSRI and SNRI use for pregnant women, history of parental epilepsy, and other covariates, rather than the use of the medication itself.

Selecting effective antidepressants for the treatment of major depressive disorder is an imprecise practice. With remission rates of about 30% after the initial therapy selection, there is a need to uncover biomarkers able to predict treatment response. This study looked at pharmacogenomic testing for drug-gene interactions to guide treatment selection. Unfortunately, they did not find significantly improved outcomes.

In this 30-minute, 0.50 credit CME activity, participants will be better able to define treatment response, remission and treatment resistance in MDD; identify patients with inadequate response to antidepressants who may benefit from treatment modification; select an appropriate next-step treatment strategy for a patient with partial response to an antidepressant; and compare pharmacologic and adverse effect profiles of SGAs approved for adjunctive treatment of MDD.

To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases due to challenges at the blood-brain barrier. James Bibb, Ph.D., and colleagues seek to change that notion with their brain-permeable compound, 25-106.

In this cross-sectional study of 586 probands and 698 first-degree relatives, cannabis use disorder and bipolar disorder II in probands were associated with an independent increase in risk of cannabis use disorder in relatives; bipolar disorder I and major depressive disorder in probands were not significantly associated with cannabis use disorder in relatives. The risk of cannabis use disorder was highest among relatives with both familial and individual history of bipolar disorder II.